spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  mifamurtide 

 HSMN NewsFeed - 18 Dec 2013
Takeda Launches New Subsidiary in Israel
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2009
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2009
Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Mar 2009
IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Nov 2008
IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Jul 2008
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Feb 2008
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2008
IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Dec 2007
IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Devices Oncology FDA
 HSMN NewsFeed - 29 May 2007
IDM Pharma Names Timothy P. Walbert as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2007
FDA Advisory Committee Reviews Data on IDM Pharma's Junovan(TM) (mifamurtide) for Treatment of Osteosarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 May 2007
IDM Pharma Appoints Robert De Vaere as Senior Vice President and CFO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Dec 2006
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Nov 2006
IDM Pharma Submits Filing for European Market Approval of Mepact(TM) (mifamurtide, Junovan(TM) in the US) in the Treatment of Osteosarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Oct 2006
IDM Pharma Submits New Drug Application to the FDA for Junovan(TM) (mifamurtide) in the Treatment of Osteosarcoma
Biopharmaceuticals Oncology FDA
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.